• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗CD19嵌合抗原受体T细胞输注后非霍奇金淋巴瘤中的糖酵解活性

Glycolytic activity following anti-CD19 CAR-T cell infusion in non-Hodgkin lymphoma.

作者信息

Vallet Nicolas, Drieu Larochelle Laurianne, Santiago-Ribeiro Maria-Joao, Villate Alban, Eloit Martin, Cirée Arnaud, Zaragoza Laura, André Virginie, Prat-Lepesant Marie, Hérault Olivier, Arbion Flavie, Blasco Hélène, Gyan Emmanuel

机构信息

Hematology and Cell Therapy, University Hospital Tours, Tours, France.

Inserm U1069 N2COx, University of Tours, Tours, France.

出版信息

Eur J Clin Invest. 2025 Feb;55(2):e14342. doi: 10.1111/eci.14342. Epub 2024 Nov 1.

DOI:10.1111/eci.14342
PMID:39487603
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11744912/
Abstract

Energy metabolism of chimeric antigen receptor-T cells (CAR-T) activation in humans remains unexplored. As a glycolytic activity surrogate, we investigated the dynamics of peripheral blood (PB) lactate in the first weeks post-CAR-T infusion. In 17 patients treated with CD28 harbording anti-CD19 CAR-T for relapsed/refractory non-Hodgkin lymphomas, PB lactate levels increased following CAR-T infusion. Elevated lactate levels correlated with longer CAR-T persistence and higher CD8+/CD4+ ratio. Peripheral blood lactate kinetics may reflect immune cells activation and be useful for bedside monitoring.

摘要

嵌合抗原受体T细胞（CAR-T）在人体内激活后的能量代谢仍未得到充分研究。作为糖酵解活性的替代指标，我们研究了CAR-T输注后最初几周外周血（PB）乳酸水平的动态变化。在17例接受携带抗CD19的CD28 CAR-T治疗复发/难治性非霍奇金淋巴瘤的患者中，CAR-T输注后PB乳酸水平升高。乳酸水平升高与CAR-T细胞的持续时间延长和较高的CD8+/CD4+比值相关。外周血乳酸动力学可能反映免疫细胞的激活情况，有助于床边监测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e6/11744912/006d135b51c8/ECI-55-e14342-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e6/11744912/08b3344ef3e7/ECI-55-e14342-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e6/11744912/006d135b51c8/ECI-55-e14342-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e6/11744912/08b3344ef3e7/ECI-55-e14342-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e6/11744912/006d135b51c8/ECI-55-e14342-g002.jpg

相似文献

1
Glycolytic activity following anti-CD19 CAR-T cell infusion in non-Hodgkin lymphoma.抗CD19嵌合抗原受体T细胞输注后非霍奇金淋巴瘤中的糖酵解活性
Eur J Clin Invest. 2025 Feb;55(2):e14342. doi: 10.1111/eci.14342. Epub 2024 Nov 1.
2
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.在 ALL 和 NHL 患者中比较自制 CD19 CAR-T 细胞。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000148.
3
Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.针对复发/难治性急性淋巴细胞白血病和非霍奇金淋巴瘤患者的首次土耳其学术性临床试验中，靶向表达CD19的B细胞的嵌合抗原受体T细胞（ISIKOK-19）的疗效和安全性分析的临床前评估
Turk J Haematol. 2020 Nov 19;37(4):234-247. doi: 10.4274/tjh.galenos.2020.2020.0070. Epub 2020 Aug 4.
4
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.双特异性 CAR-T 细胞靶向治疗复发或难治性 B 细胞非霍奇金淋巴瘤患者：一项 I/II 期试验。
Blood Cancer J. 2024 Aug 7;14(1):130. doi: 10.1038/s41408-024-01105-8.
5
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma.输注后 PD-1+CD8+CAR T 细胞可识别非霍奇金淋巴瘤中对 CD19 CAR T 细胞治疗有反应的患者。
Blood Adv. 2024 Jun 25;8(12):3140-3153. doi: 10.1182/bloodadvances.2023012073.
6
Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.第四代抗 CD19 嵌合抗原受体 T 细胞治疗复发/难治性 B 细胞非霍奇金淋巴瘤的 I 期临床试验。
Front Immunol. 2020 Nov 27;11:564099. doi: 10.3389/fimmu.2020.564099. eCollection 2020.
7
Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen.三种靶向CD79b的新型嵌合抗原受体用于治疗非霍奇金淋巴瘤的临床前开发及靶抗原丢失的特征分析
J Immunother Cancer. 2024 Dec 18;12(12):e009485. doi: 10.1136/jitc-2024-009485.
8
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.体内第二代与第三代 CD19 特异性 CAR-T 细胞在 B 细胞非霍奇金淋巴瘤中的命运和活性。
Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.
9
Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.CD20 耐药性非霍奇金淋巴瘤中 CD19-CAR 自然杀伤细胞治疗的转录组和分泌反应的相互作用动力学。
Leukemia. 2020 May;34(5):1291-1304. doi: 10.1038/s41375-019-0663-x. Epub 2019 Nov 26.
10
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.B细胞非霍奇金淋巴瘤患者自体造血干细胞移植后中枢记忆来源的CD19嵌合抗原受体T细胞疗法的1期研究。
Blood. 2016 Jun 16;127(24):2980-90. doi: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26.

本文引用的文献

1
Clinical Warburg effect in lymphoma patients admitted to intensive care unit.入住重症监护病房的淋巴瘤患者的临床瓦伯格效应
Ann Intensive Care. 2023 Oct 5;13(1):97. doi: 10.1186/s13613-023-01192-z.
2
A major role for CD4 T cells in driving cytokine release syndrome during CAR T cell therapy.CD4 T 细胞在 CAR T 细胞治疗中驱动细胞因子释放综合征的主要作用。
Cell Rep Med. 2023 Sep 19;4(9):101161. doi: 10.1016/j.xcrm.2023.101161. Epub 2023 Aug 17.
3
Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases.
鉴定导致免疫疗法和人类疾病细胞因子释放的基因组决定因素。
J Transl Med. 2022 Jul 28;20(1):338. doi: 10.1186/s12967-022-03531-3.
4
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.阻断或缺失 IFNγ 可减少血液系统恶性肿瘤中巨噬细胞的活化而不影响 CAR T 细胞的功能。
Blood Cancer Discov. 2022 Mar 1;3(2):136-153. doi: 10.1158/2643-3230.BCD-21-0181.
5
Mitochondrial arginase-2 is essential for IL-10 metabolic reprogramming of inflammatory macrophages.线粒体精氨酸酶 2 对于炎性巨噬细胞中 IL-10 的代谢重编程是必需的。
Nat Commun. 2021 Mar 5;12(1):1460. doi: 10.1038/s41467-021-21617-2.
6
Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome.嵌合抗原受体 T 细胞通过 GSDME 介导热激细胞焦亡引发细胞因子释放综合征。
Sci Immunol. 2020 Jan 17;5(43). doi: 10.1126/sciimmunol.aax7969.
7
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.单核细胞衍生的白细胞介素-1 和白细胞介素-6 对于 CAR T 细胞引起的细胞因子释放综合征和神经毒性是有差异需求的。
Nat Med. 2018 Jun;24(6):739-748. doi: 10.1038/s41591-018-0036-4. Epub 2018 May 28.
8
CAR T cell immunotherapy for human cancer.嵌合抗原受体 T 细胞免疫疗法治疗人类癌症。
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.
9
Microbial stimulation of different Toll-like receptor signalling pathways induces diverse metabolic programmes in human monocytes.不同Toll样受体信号通路的微生物刺激在人类单核细胞中诱导出多样的代谢程序。
Nat Microbiol. 2016 Dec 19;2:16246. doi: 10.1038/nmicrobiol.2016.246.
10
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity.L-精氨酸调节T细胞代谢并增强其存活及抗肿瘤活性。
Cell. 2016 Oct 20;167(3):829-842.e13. doi: 10.1016/j.cell.2016.09.031. Epub 2016 Oct 13.